New indications for exenatide therapy of type 2 diabetes mellitus
Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatid...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/5496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327350052814848 |
|---|---|
| author | Olga Konstantinovna Vikulova Marina Vladimirovna Shestakova |
| author_facet | Olga Konstantinovna Vikulova Marina Vladimirovna Shestakova |
| author_sort | Olga Konstantinovna Vikulova |
| collection | DOAJ |
| description | Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatide(Byetta) is the first drug of this class approved for the use as monotherapy. This paper presents a detailed review of the available data on thescope of exenatide effects and the results of its clinical studies that confirm high efficiency of Byetta used for both monotherapy and combined therapyof DM2. |
| format | Article |
| id | doaj-art-966c47654fdf45d8a1986ff7d62d681c |
| institution | Kabale University |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2010-09-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-966c47654fdf45d8a1986ff7d62d681c2025-08-20T03:47:54ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-09-011339810410.14341/2072-0351-54965454New indications for exenatide therapy of type 2 diabetes mellitusOlga Konstantinovna Vikulova0Marina Vladimirovna Shestakova1Endocrinological Research Centre, MoscowEndocrinological Research Centre, MoscowObesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatide(Byetta) is the first drug of this class approved for the use as monotherapy. This paper presents a detailed review of the available data on thescope of exenatide effects and the results of its clinical studies that confirm high efficiency of Byetta used for both monotherapy and combined therapyof DM2.https://www.dia-endojournals.ru/jour/article/view/5496type 2 diabetes mellitusobesityincretin mimeticsexenatidebyetta |
| spellingShingle | Olga Konstantinovna Vikulova Marina Vladimirovna Shestakova New indications for exenatide therapy of type 2 diabetes mellitus Сахарный диабет type 2 diabetes mellitus obesity incretin mimetics exenatide byetta |
| title | New indications for exenatide therapy of type 2 diabetes mellitus |
| title_full | New indications for exenatide therapy of type 2 diabetes mellitus |
| title_fullStr | New indications for exenatide therapy of type 2 diabetes mellitus |
| title_full_unstemmed | New indications for exenatide therapy of type 2 diabetes mellitus |
| title_short | New indications for exenatide therapy of type 2 diabetes mellitus |
| title_sort | new indications for exenatide therapy of type 2 diabetes mellitus |
| topic | type 2 diabetes mellitus obesity incretin mimetics exenatide byetta |
| url | https://www.dia-endojournals.ru/jour/article/view/5496 |
| work_keys_str_mv | AT olgakonstantinovnavikulova newindicationsforexenatidetherapyoftype2diabetesmellitus AT marinavladimirovnashestakova newindicationsforexenatidetherapyoftype2diabetesmellitus |